A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive BCell Acute Lymphoblastic Leukemia

被引：1
|
作者：
Short, Nicholas J. [1 ]
Kantarjian, Hagop [1 ]
Alvarado, Yesid [1 ]
Burger, Jan A. [1 ]
Jain, Nitin [1 ]
Konopleva, Marina [1 ]
Ravandi, Farhad [1 ]
DiNardo, Courtney D. [1 ]
Masarova, Lucia [1 ]
Sasaki, Koji [1 ]
Thompson, Philip A. [1 ]
Ferrajoli, Alessandra [1 ]
Jacob, Jovitta [1 ]
Milton, Anna [1 ]
Garris, Rebecca [1 ]
Jabbour, Elias J. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-154124
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2299
引用
收藏
页数：6
相关论文
共 50 条
  • [31] A Phase II Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of the ITCC-059 Study
    Brivio, Erica
    Locatelli, Franco
    Thano, Adriana
    Petit, Arnaud
    Vormoor, Britta Julia
    Rives, Susana
    Bielorai, Bella
    Rossig, Claudia
    Rizzari, Carmelo
    Van der Velden, Vincent H. J.
    Ammerlaan, Anneke C. J.
    Den Boer, Monique L.
    Sleight, Barbara
    Engstler, Gernot
    Stary, Jan
    Sirvent, Francisco Jose Bautista
    Chen-Santel, Christiane
    Bruno, Benedicte
    Bertrand, Yves
    Rialland, Fanny
    Plat, Genevieve
    Reinhardt, Dirk
    Vinti, Luciana
    von Stackelberg, Arend
    Zwaan, Christian Michel
    BLOOD, 2020, 136
  • [32] Measurable Residual Disease in Acute Lymphoblastic Leukemia: Techniques and Therapeutic Utility
    Muffly, Lori
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (07) : 419 - 421
  • [33] Molecular and cellular markers for measurable residual disease in acute lymphoblastic leukemia
    Juarez-Avendano, Gerardo
    Mendez-Ramirez, Nereida
    Luna-Silva, Nuria C.
    Gomez-Almaguer, David
    Pelayo, Rosana
    Balandran, Juan C.
    BOLETIN MEDICO DEL HOSPITAL INFANTIL DE MEXICO, 2021, 78 (03): : 159 - 170
  • [34] PREDICTING MEASURABLE RESIDUAL DISEASE FOR ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS POSTTRANSPLANTATION
    Wang, Yue-Wen
    Fu, Guo-Mei
    Xu, Lan-Ping
    Wang, Yu
    Cheng, Yi-Fei
    Zhang, Yuan-Yuan
    Zhang, Xiao-Hui
    Liu, Yan-Rong
    Liu, Kai-Yan
    Huang, Xiao-Jun
    Chang, Ying-Jun
    BONE MARROW TRANSPLANTATION, 2024, 59 : 498 - 498
  • [35] Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial
    Jabbour, Elias
    Goekbuget, Nicola
    Advani, Anjali
    Stelljes, Matthias
    Stock, Wendy
    Liedtke, Michaela
    Martinelli, Giovanni
    O'Brien, Susan
    Wang, Tao
    Laird, A. Douglas
    Vandendries, Erik
    Neuhof, Alexander
    Nguyen, Kevin
    Dakappagari, Naveen
    DeAngelo, Daniel J.
    Kantarjian, Hagop
    LEUKEMIA RESEARCH, 2020, 88
  • [36] Inotuzumab ozogamicin and blinatumomab sequential therapy for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia
    Ueda, Tomoaki
    Fukushima, Kentaro
    Kusakabe, Shinsuke
    Yoshida, Koki
    Suga, Makiko
    Nakai, Ritsuko
    Koike, Midori
    Hino, Akihisa
    Akuta, Keigo
    Toda, Jun
    Nagate, Yasuhiro
    Doi, Yukiko
    Fujita, Jiro
    Yokota, Takafumi
    Hosen, Naoki
    LEUKEMIA RESEARCH REPORTS, 2022, 17
  • [37] Burden of hospitalization in acute lymphoblastic leukemia patients treated with Inotuzumab Ozogamicin versus standard chemotherapy treatment
    Marks, David, I
    van Oostrum, Ilse
    Mueller, Sabrina
    Welch, Verna
    Vandendries, Erik
    Loberiza, Fausto R.
    Bohme, Sarah
    Su, Yun
    Stelljes, Matthias
    Kantarjian, Hagop M.
    CANCER MEDICINE, 2019, 8 (13): : 5959 - 5968
  • [38] GIMEMA ALL2418| UPDATED INTERIM ANALYSIS OF A PHASE IIA STUDY OF FEASIBILITY AND EFFECTIVENESS OF INOTUZUMAB OZOGAMICIN IN ADULT PATIENTS WITH B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH POSITIVE MINIMAL RESIDUAL DISEASE
    Martinelli, G.
    Piciocchi, A.
    Chiaretti, S.
    Papayannidis, C.
    Salutari, P.
    Olivieri, A.
    Zappasodi, P.
    Rambaldi, A.
    Fracchiolla, N.
    Cavallari, M.
    Soddu, S.
    Abbenante, M.
    Candoni, A.
    Cattaneo, C.
    Gigli, F.
    Marino, M. R.
    Messina, M.
    Grillo, G.
    Ferrara, F.
    Siragusa, S.
    De Fabritiis, P.
    Lico, A.
    Audisio, E.
    Bonifacio, M.
    Lemoli, R. M.
    Mattei, D.
    Lunghi, M.
    Cilloni, D.
    Ferrari, A.
    Nanni, J.
    Della Starza, I.
    Simonetti, G.
    De Propris, M.
    Bochicchio, M. T.
    Vignetti, M.
    Fazi, P.
    Marconi, G.
    HAEMATOLOGICA, 2024, 109 : 79 - 80
  • [39] BUDGET IMPACT ANALYSIS OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA IN ALGERIA
    Djemai, S.
    Derki, S.
    Enzrati, Jalal J.
    Russell-Smith, T. A.
    VALUE IN HEALTH, 2024, 27 (12) : S83 - S84
  • [40] Inotuzumab Ozogamicin Salvage Monotherapy for the Treatment of Relapsed/Refractory Acute B-Cell Lymphoblastic Leukemia
    Darcin, Tahir
    Yigenoglu, Tugce Nur
    Sahin, Derya
    Bakirtas, Mehmet
    Basci, Semih
    Merdin, Alparslan
    Yildiz, Jale
    Ulu, Bahar Uncu
    Tetik, Aysegul
    Iskender, Dicle
    Cakar, Merih Kizil
    Dal, Mehmet Sinan
    Altuntas, Fevzi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S192 - S193
12345